# Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

Source: https://onco.cc/trials/nct06687681/  
OnCo record `nct06687681` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of NK cell therapy in glioma & glioblastoma, run by Marzieh Ebrahimi, now recruiting.

## Summary

Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas is a phase 2 interventional study registered as NCT06687681 by Marzieh Ebrahimi, with 40 participants planned, started 2024-11-25 and due to reach its primary completion in 2025-11-25. Interventions recorded: NK cell therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06687681
- Phase: 2
- Setting: Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial
- Sponsor: Marzieh Ebrahimi
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06687681: https://clinicaltrials.gov/study/NCT06687681

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06687681.json